Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GlobeNewswire

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
News headline image
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
NOTICE TO DISREGARD -- ICARO Media Group
From ICARO Media Group
Via GlobeNewswire
News headline image
HeroFlow Announces Expansion of Access to “The AI Employee,” the 24/7 Virtual Receptionist That Never Calls In Sick
From HeroFlow
Via GlobeNewswire
News headline image
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA Factory
From Faraday Future
Via GlobeNewswire
Tickers FFAI
News headline image
The Ohio State University’s Caleb Downs Named Winner of Lott IMPACT Trophy Presented by Allied Universal
From Allied Universal Corp
Via GlobeNewswire
News headline image
Skyline Digital Marketing Introduces Proprietary Skyline Methodology to Strengthen Data-Driven Business Growth
From Skyline Digital Marketing
Via GlobeNewswire
News headline image
WAL Investor News: If You Have Suffered Losses in Western Alliance Bancorporation (NYSE: WAL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Tickers WAL
News headline image
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Tickers HCM LSE
News headline image
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
Tickers IMMX
News headline image
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Tickers IMMX
News headline image
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
From Lime & Lemon Indian Grill & Bar
Via GlobeNewswire
News headline image
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
From Miltenyi Biomedicine
Via GlobeNewswire
News headline image
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
News headline image
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
News headline image
Rally House Breaks Company Online Sales Record After Electric Sports Weekend
From Rally House
Via GlobeNewswire
News headline image
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
News headline image
Nayax Considering an Offering of Notes and Warrants in Israel
From Nayax Ltd.
Via GlobeNewswire
Tickers NYAX
News headline image
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
From Prime Medicine, Inc.
Via GlobeNewswire
Tickers PRME
News headline image
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Stride, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LRN
From The Rosen Law Firm PA
Via GlobeNewswire
Tickers LRN
News headline image
Balancer Announcement: If You Have Suffered Losses in Balancer Cryptocurrency, You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Tickers CRMT
News headline image
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
News headline image
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
News headline image
DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
From The Rosen Law Firm PA
Via GlobeNewswire
Tickers DXCM
News headline image
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.